SciRhom

SciRhom GmbH is a biotechnology company based in Martinsried, Germany, founded in 2016.

The company focuses on developing first-in-class humanized antibodies that target iRhom2 to treat life-threatening autoimmune diseases. With a mission to translate advanced scientific findings into effective therapies, SciRhom leverages over a decade of research led by notable scientists. The company's proprietary technology selectively inhibits pro-inflammatory pathways while preserving essential protective roles in the body. SciRhom's lead candidate, SRS-878, is currently in preclinical and early clinical development, with plans to initiate first-in-human trials in Austria. The therapies aim to address conditions such as rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematosus. SciRhom operates primarily in the B2B space, partnering with pharmaceutical companies and healthcare providers to bring its innovative solutions to patients.